NEW YORK, July 28, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT).Shareholders who purchased shares of SRPT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/sarepta-loss-submission-form/?id=158125&from=4CLASS PERIOD: June 22, 2023 to J ...

NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Sarepta Therapeutics, Inc. (NASDAQ: SRPT) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Sarepta, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/sarepta-therapeutics-inc-class-action. Investors have until August 25, 2025, to as ...

NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the "Class") who purchased or acquired the securities of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) between June 22, 2023 and June 24, 2025, inclusive. Should You Join This Class Action Lawsuit? If you purchased or acquired Sarepta securities, and/or would like to discuss your legal rights and options please visit Sare ...

Group 1 - Sarepta Therapeutics (SRPT) has experienced a significant decline in stock value, down more than 90% year-to-date [1] - The company has faced a series of negative events, including paused drug shipments and patient deaths [1]

Core Viewpoint - A lawsuit has been filed against Sarepta Therapeutics, Inc. and its senior executives for potential violations of federal securities laws, particularly concerning the safety claims of its product Elevidys [1][2]. Company Overview - Sarepta Therapeutics is a biopharmaceutical company focused on developing treatments for rare diseases, with Elevidys being its most significant product aimed at treating Duchenne muscular dystrophy [3]. Allegations and Impact - The lawsuit alleges that Sarepta misrepresented the safety profile of Elevidys, claiming that the benefits outweighed the risks, while in reality, the treatment has been linked to fatal acute liver failure in some patients [3]. - Following the announcement of patient deaths related to Elevidys, Sarepta's stock experienced significant declines, with a drop of over 27% on March 18, 2025, and a further decline of more than 42% on June 16, 2025 [4][5]. Legal Proceedings - The case is pending in the U.S. District Court for the Southern District of New York, with investors having until August 25, 2025, to seek lead plaintiff status [2].

Core Viewpoint - Sarepta Therapeutics has clarified that the death of an 8-year-old child is not related to its gene therapy product, Elevidys, and has reported the incident to the FDA on June 18 [1] Company Summary - Sarepta Therapeutics is actively addressing concerns regarding the safety of its gene therapy product, Elevidys, following the reported death of a child [1] - The company has taken the necessary steps to inform the FDA about the incident, indicating a commitment to regulatory compliance and transparency [1] Industry Summary - The incident highlights ongoing scrutiny and regulatory oversight in the gene therapy sector, particularly concerning the safety profiles of new treatments [1] - The response from Sarepta Therapeutics may influence investor confidence and public perception of gene therapy products in the market [1]

US regulators said they are investigating the death of an 8-year-old boy who received a gene therapy from Sarepta Therapeutics https://t.co/RKyzBaUpTz ...

NEW YORK, July 25, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sarepta investors who were adversely affected by alleged securities fraud between June 22, 2023 and June 24, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/sarepta-lawsuit-submi ...

Core Opinion - The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion on the conditional marketing authorization for Elevidys, a gene therapy for Duchenne muscular dystrophy (DMD) in ambulatory children aged three to seven years [1][2]. Group 1: Clinical Data and Efficacy - The CHMP's opinion was based on data from the largest gene therapy clinical program for DMD, including the pivotal Phase 3 EMBARK study, which indicated that Elevidys provided sustained stabilization or slowing of disease progression [2]. - Over 900 individuals with DMD have been treated with Elevidys, with 760 being ambulatory; although the primary endpoint was not met in EMBARK after one year, significant improvements were observed in secondary endpoints compared to placebo [3]. - Longer-term efficacy data submitted to the EMA included two-year results from the EMBARK study and a three-year pooled efficacy analysis from other studies, showing clinically meaningful improvements in motor function [4]. Group 2: Regulatory and Market Impact - Sarepta Therapeutics announced a voluntary and temporary pause of all U.S. shipments of Elevidys effective July 22, following a senior FDA official's statement that additional clinical data would be required to validate Elevidys' safety profile [4][5]. - Analysts expressed uncertainty regarding the FDA's requirements for resuming shipments, noting that requiring another trial for ambulatory patients would be unusual given Elevidys' existing full approval for that group [6]. - The stock price of Sarepta Therapeutics fell by 7.53% to $11.91, reflecting market pressure due to the ongoing uncertainty surrounding the product's status [9]. Group 3: Partnerships and Financial Implications - Arrowhead Pharmaceuticals reported that Sarepta has faced setbacks in unrelated products and programs, but expects to earn the first $100 million soon and the remaining $200 million by year-end [8]. - Should Sarepta fail to meet payment milestones associated with the enrollment of ARO-DM1 cohorts, Arrowhead would have the right to terminate the agreement regarding ARO-DM1 [9].

A new report saying Serepta would need to conduct new studies in order to show the FDA that its musculardrophe drug Elevus is safe. And just this morning, EU regulators not recommending approval of that treatment. As a result, that stock is down another 13%.Joining us right now on that and what to expect from the other biotech names reporting next week is Saline Richtor, lead biotech analyst at Goldman Sachs. and Saline, let's go ahead and start with the news of the day since it's out with Surrepta. Um, jus ...